Trial Profile
A Phase 1, Open-Label, 3-Period, Randomized, Crossover Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC 0973 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Rabeprazole
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 12 Jul 2016 Time frame in primary endpoint has changed from 8 weeks to Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose.
- 23 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2011 New trial record